U.S. Sickle Cell Disease Treatment Market Size, Share & COVID-19 Impact Analysis, By Treatment Modality [Bone Marrow Transplant, Blood Transfusion, Pharmacotherapy {Hydroxyurea, Branded Products (Endari, Adakveo, Oxbryta, Zynteglo, PYRUKYND (Mitapivat), CTX001, Inclacumab, MGTA-145, Vamifeport (VIT-2763), ALXN1820, FT-4202, and GBT021601)}], By End-user (Hospitals, Specialty Clinics, and Others), and Country Forecast, 2023-2030

Last Updated: February 17, 2025 | Format: PDF | Report ID: FBI108646

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2030
Base Year	2022
Estimated Year	2023
Forecast Period	2023-2030
Historical Period	2019-2021
Growth Rate	CAGR of 17.3% from 2023-2030
Unit	Value (USD Billion)
Segmentation	By Treatment Modality Bone Marrow Transplant Blood Transfusion Pharmacotherapy Hydroxyurea Branded Products Adakveo Oxbryta Endari Zynteglo CTX001 PYRUKYND (Mitapivat) Inclacumab Vamifeport (VIT-2763) ALXN1820 MGTA-145 FT-4202 GBT021601
Segmentation	By End-user Hospitals Specialty Clinics Others